CIK 0002079109
- Emerging growth company
Veraxa Biotech AG - Post de-SPAC
Sign in to watch- Ticker
- VRXA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- Other
- Phone
- +41 443858450
- Business address
- TALACKER 35, ZURICH, Switzerland, 8001
- Former names
- Veraxa Biotech Holding AG
Securities
- VRXA Ordinary Shares Nasdaq
- VRXAW Warrants Nasdaq
- 4 Open-market buy Director bought 10,000 shares at an average $1.00 ($9,983)
- 4 Open-market buy Director bought 30,000 shares at $1.09 ($32,700)
- 6-K Event Report of Foreign Issuer
- 3 Insider Initial Statement of Ownership
- 424B3 Offering Prospectus
- 424B3 Offering Prospectus
- 6-K Event Report of Foreign Issuer
- 4 Open-market buy Director bought 50,000 shares at $1.50 ($75,000)
- 4 Open-market buy Chief Executive Officer bought 5,000 shares at $1.53 ($7,650)
- 6-K Event Report of Foreign Issuer
- 3 Insider Initial Statement of Ownership
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 424B5 Offering Prospectus
- 424B5 Offering Prospectus
- EFFECT Other Notice of Effectiveness
- EFFECT Other Notice of Effectiveness
- F-1/A Offering Registration Statement for Certain Foreign Private Issuers
- F-1/A Offering Registration Statement for Certain Foreign Private Issuers
- F-1 Offering Registration Statement for Certain Foreign Private Issuers
- F-1 Offering Registration Statement for Certain Foreign Private Issuers
Page 1 of 3 · 56 filings